Literature DB >> 12826949

Surgical management of symptomatic talocalcaneal coalitions by resection of the sustentaculum tali.

David E Westberry1, Jon R Davids, William Oros.   

Abstract

Previously described techniques for surgical resection of the subtalar coalitions are technically demanding, with poor outcomes related to incomplete resection and recurrence of the coalition. A new technique, involving complete excision of the involved portion of the sustentaculum tali, has been developed at the authors' institution. A retrospective review of 10 patients with 12 coalitions was performed. The index procedure was performed at an average age of 12.7 years, with a mean follow-up of 5.1 years. Preoperative CT scans obtained to assess the extent of the coalition were analyzed. The AOFAS Hindfoot Questionnaire was used postoperatively to assess the patients' overall outcome and satisfaction with the procedure. Overall, there were eight excellent results and three good results. The postoperative mean AOFAS score was 90 compared with a preoperative score of 46. There have been no recurrences of the coalition or progressive foot malalignment in this series of patients.

Entities:  

Mesh:

Year:  2003        PMID: 12826949

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  2 in total

1.  Coalition resection and medial displacement calcaneal osteotomy for treatment of symptomatic talocalcaneal coalition: functional and clinical outcome.

Authors:  Ossama El Shazly; Mohammed Mokhtar; Nasef Abdelatif; Mohamed Hegazy; Rana El Hilaly; Abeer El Zohairy; Eman Tawfik
Journal:  Int Orthop       Date:  2014-09-25       Impact factor: 3.075

2.  Operative versus nonoperative treatment in children with painful rigid flatfoot and talocalcaneal coalition.

Authors:  Giovanni Luigi Di Gennaro; Stefano Stallone; Eleonora Olivotto; Paola Zarantonello; Marina Magnani; Tullia Tavernini; Stefano Stilli; Giovanni Trisolino
Journal:  BMC Musculoskelet Disord       Date:  2020-03-24       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.